Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Sold by Woodline Partners LP

Woodline Partners LP trimmed its stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 622,682 shares of the company's stock after selling 621,869 shares during the period. Woodline Partners LP owned 0.98% of Larimar Therapeutics worth $2,410,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of LRMR. Velan Capital Investment Management LP bought a new position in shares of Larimar Therapeutics in the 4th quarter worth about $70,000. Sphera Funds Management LTD. increased its stake in shares of Larimar Therapeutics by 9.9% in the 4th quarter. Sphera Funds Management LTD. now owns 455,604 shares of the company's stock worth $1,763,000 after acquiring an additional 41,126 shares in the last quarter. ProShare Advisors LLC bought a new position in shares of Larimar Therapeutics in the 4th quarter worth about $58,000. Janus Henderson Group PLC increased its stake in shares of Larimar Therapeutics by 15.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company's stock worth $24,936,000 after acquiring an additional 876,431 shares in the last quarter. Finally, Graham Capital Management L.P. bought a new position in shares of Larimar Therapeutics in the 4th quarter worth about $54,000. 91.92% of the stock is owned by hedge funds and other institutional investors.

Larimar Therapeutics Stock Down 1.5%

Shares of NASDAQ LRMR traded down $0.04 during trading hours on Friday, hitting $2.27. 397,356 shares of the stock were exchanged, compared to its average volume of 778,414. The company has a market cap of $145.02 million, a PE ratio of -1.96 and a beta of 0.93. The firm has a fifty day moving average price of $2.10 and a 200-day moving average price of $3.47. Larimar Therapeutics, Inc. has a 12 month low of $1.61 and a 12 month high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). As a group, equities analysts anticipate that Larimar Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Robert W. Baird reduced their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. HC Wainwright raised their price objective on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, March 25th. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Finally, Guggenheim restated a "buy" rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $20.43.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.